Retatrutide has emerged as a new pharmaceutical in the fight against obesity. This novel drug, categorized as a dual GLP-1 and GIP receptor agonist, demonstrates promising results in research studies. By stimulating these receptors, Retatrutide controls cravings, {promotesenergy expenditure, and ult